Form 4: Regeneron VP Controller Receives Equity Awards

Regeneron Pharmaceuticals' VP Controller, Jason Pitofsky, received new equity awards including restricted stock and stock options, alongside a related stock disposition.

Summary

• Jason Pitofsky, VP Controller of Regeneron Pharmaceuticals, Inc. (REGN), acquired 2,064 shares of Common Stock as a restricted stock award on December 5, 2025, with a grant price of $0.0.
• The restricted stock award vests 50% on December 5, 2027, and the remaining 50% on December 5, 2029.
• Pitofsky also acquired 2,261 Non-Qualified Stock Options on December 5, 2025, with an exercise price of $726.71.
• These stock options vest in four equal annual installments, commencing one year after the grant date (December 5, 2026), and expire on December 5, 2035.
• On December 8, 2025, Pitofsky disposed of 989 shares of Common Stock at a price of $712.94 per share, likely for tax withholding purposes related to the equity awards.
• Following these transactions, Pitofsky directly beneficially owns 5,308 shares of Common Stock, with additional indirect ownership of 31 shares via a 401(k) Plan and 179 shares by his spouse.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects routine executive compensation and retention, which is generally a healthy sign for corporate governance and management alignment, despite a minor disposition for tax purposes.

Positives

• The grant of restricted stock and stock options aligns the executive's long-term interests with those of shareholders, incentivizing performance.
• The awards are part of a structured long-term incentive plan, indicating a commitment to executive retention and motivation.

Negatives

• The disposition of 989 shares, while likely for tax obligations, reduces the executive's direct beneficial ownership of common stock.

Future Outlook

The equity awards, with their multi-year vesting schedules extending to 2029 and option expiration in 2035, indicate a long-term retention strategy for the VP Controller, aligning future performance with shareholder value creation.

Industry Context

The granting of restricted stock and stock options is a standard practice in the biotechnology and pharmaceutical industry for executive compensation, aiming to attract, retain, and motivate key personnel by linking their financial incentives to the company's long-term stock performance.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity awards align management's financial interests with shareholder value creation over the long term.
• Employees: Standard executive compensation practices can influence overall compensation philosophy and morale within the company.

Next Steps

• Vesting of restricted stock on December 5, 2027, and December 5, 2029.
• Annual vesting installments for stock options commencing December 5, 2026, through December 5, 2029.
• Potential exercise of stock options prior to their expiration on December 5, 2035.

Key Dates

Keywords

Regeneron Pharmaceuticals, REGN, Form 4, Insider Transaction, Equity Award, Restricted Stock, Stock Options, Executive Compensation, Corporate Governance